Page last updated: 2024-12-07

glycolithocholic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Glycolithocholic acid (GLCA) is a bile acid synthesized in the liver from cholic acid. It is a primary bile acid, meaning it is directly synthesized in the liver, and is conjugated with glycine to form glycocholic acid. GLCA is a potent activator of the farnesoid X receptor (FXR), a nuclear receptor that plays a key role in the regulation of bile acid synthesis and metabolism. GLCA has been shown to have various effects, including: reducing cholesterol levels, inhibiting inflammation, and promoting insulin sensitivity. It is studied for its potential therapeutic applications in various diseases, including non-alcoholic fatty liver disease (NAFLD), obesity, and type 2 diabetes. Research focuses on understanding its mechanism of action, optimizing its therapeutic potential, and investigating its safety and efficacy in clinical trials.'

glycolithocholic acid: RN given refers to (3alpha,5beta)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

glycolithocholic acid : The glycine conjugate of lithocholic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
GlycinegenusA non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter.[MeSH]FabaceaeThe large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH]

Cross-References

ID SourceID
PubMed CID115245
CHEMBL ID258818
CHEBI ID37998
SCHEMBL ID736797
MeSH IDM0089917

Synonyms (48)

Synonym
BIDD:PXR0159
glycolithocholic acid
474-74-8
glycine, n-((3-alpha,5-beta)-3-hydroxy-24-oxocholan-24-yl)-
glycine, n-(3-alpha-hydroxy-5-beta-cholan-24-oyl)-
n-((3-alpha,5-beta)-3-hydroxy-24-oxocholan-24-yl)glycine
glycine, n-((3alpha,5beta)-3-hydroxy-24-oxocholan-24-yl)-
lithocholylglycine
lithocholic acid glycine conjugate
PDSP2_001234
CHEBI:37998 ,
n-(3alpha-hydroxy-5beta-cholan-24-oyl)glycine
CHEMBL258818 ,
LMST05030009
q53gv75cjg ,
unii-q53gv75cjg
glycine, n-[(3a,5b)-3-hydroxy-24-oxocholan-24-yl]-
bdbm50375588
3a-hydroxy-5b-cholanic acid glycine ester
SCHEMBL736797
glykolithocholsaure
3.alpha.-hydroxy-n-(carboxymethyl)-5.beta.-cholan-24-amide
n-((3.alpha.,5.beta.)-3-hydroxy-24-oxocholan-24-yl)glycine
3.alpha.-hydroxy-5.beta.-cholanoylglycine
glycine, n-((3.alpha.,5.beta.)-3-hydroxy-24-oxocholan-24-yl)-
glycine, n-(3.alpha.-hydroxy-5.beta.-cholan-24-oyl)-
5.beta.-cholan-24-amide, n-(carboxymethyl)-3.alpha.-hydroxy-
n-(3.alpha.-hydroxy-5.beta.-cholanoyl)glycine
3.alpha.-hydroxy-5.beta.-cholanic acid glycine ester
n-(3alpha-hydroxy-5beta-cholan-24-oyl)-glycine
AKOS030240641
lithocholoyglycine
n-(carboxymethyl)-3a-hydroxy-5b-cholan-24-amide
3a-hydroxy-n-(carboxymethyl)-5b-cholan-24-amide
n-(3a-hydroxy-5b-cholan-24-oyl)-glycine
n-(3a-hydroxy-5b-cholanoyl)glycine
3a-hydroxy-5b-cholanoylglycine
3alpha-hydroxy-5beta-cholan-24-oic acid n-(carboxymethyl)amide
lithocholic acid glycine conjugic acid
5beta-cholanic acid-3alpha-ol n-(carboxymethyl)-amide
Q27117337
st 24:1;o2;g
n-(3,24-dihydroxycholan-24-ylidene)glycine
DTXSID00963828
((r)-4-((3r,5r,8r,9s,10s,13r,14s,17r)-3-hydroxy-10,13-dimethylhexadecahydro-1h-cyclopenta[a]phenanthren-17-yl)pentanoyl)glycine
MS-27757
HY-116374
CS-0059532

Research Excerpts

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
bile acid glycine conjugateAmide of a bile acid with glycine.
N-acylglycineAn N-acyl-amino acid in which amino acid specified is glycine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (7)

PathwayProteinsCompounds
Bile Acid Biosynthesis1761
Congenital Bile Acid Synthesis Defect Type II1761
Congenital Bile Acid Synthesis Defect Type III1761
Familial Hypercholanemia (FHCA)1761
Zellweger Syndrome1761
Cerebrotendinous Xanthomatosis (CTX)1761
27-Hydroxylase Deficiency1761

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Ubiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)IC50 (µMol)50.00005.40006.10006.8000AID1802686; AID1802687
Vitamin D3 receptorHomo sapiens (human)IC50 (µMol)45.05000.00000.43746.4300AID1277414; AID1277417
Ephrin type-A receptor 2Homo sapiens (human)IC50 (µMol)93.48900.00080.04360.2626AID728707; AID728719
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Vitamin D3 receptorHomo sapiens (human)EC50 (µMol)150.00000.00000.14232.1400AID1277413; AID1277415
G-protein coupled bile acid receptor 1Homo sapiens (human)EC50 (µMol)0.54000.02372.52598.9000AID324923
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (86)

Processvia Protein(s)Taxonomy
negative regulation of transcription by RNA polymerase IIUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
proteolysisUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
muscle organ developmentUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
protein deubiquitinationUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
circadian regulation of gene expressionUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
entrainment of circadian clock by photoperiodUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
locomotor rhythmUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
positive regulation of mitotic cell cycleUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
circadian behaviorUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
protein stabilizationUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
regulation of signal transduction by p53 class mediatorUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
negative regulation of DNA-templated transcriptionVitamin D3 receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIVitamin D3 receptorHomo sapiens (human)
cell morphogenesisVitamin D3 receptorHomo sapiens (human)
skeletal system developmentVitamin D3 receptorHomo sapiens (human)
calcium ion transportVitamin D3 receptorHomo sapiens (human)
intracellular calcium ion homeostasisVitamin D3 receptorHomo sapiens (human)
lactationVitamin D3 receptorHomo sapiens (human)
negative regulation of cell population proliferationVitamin D3 receptorHomo sapiens (human)
positive regulation of gene expressionVitamin D3 receptorHomo sapiens (human)
negative regulation of keratinocyte proliferationVitamin D3 receptorHomo sapiens (human)
positive regulation of vitamin D 24-hydroxylase activityVitamin D3 receptorHomo sapiens (human)
positive regulation of bone mineralizationVitamin D3 receptorHomo sapiens (human)
phosphate ion transmembrane transportVitamin D3 receptorHomo sapiens (human)
bile acid signaling pathwayVitamin D3 receptorHomo sapiens (human)
mRNA transcription by RNA polymerase IIVitamin D3 receptorHomo sapiens (human)
positive regulation of keratinocyte differentiationVitamin D3 receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIVitamin D3 receptorHomo sapiens (human)
decidualizationVitamin D3 receptorHomo sapiens (human)
intestinal absorptionVitamin D3 receptorHomo sapiens (human)
apoptotic process involved in mammary gland involutionVitamin D3 receptorHomo sapiens (human)
positive regulation of apoptotic process involved in mammary gland involutionVitamin D3 receptorHomo sapiens (human)
regulation of calcidiol 1-monooxygenase activityVitamin D3 receptorHomo sapiens (human)
mammary gland branching involved in pregnancyVitamin D3 receptorHomo sapiens (human)
vitamin D receptor signaling pathwayVitamin D3 receptorHomo sapiens (human)
positive regulation of vitamin D receptor signaling pathwayVitamin D3 receptorHomo sapiens (human)
response to bile acidVitamin D3 receptorHomo sapiens (human)
multicellular organism developmentVitamin D3 receptorHomo sapiens (human)
cell differentiationVitamin D3 receptorHomo sapiens (human)
skeletal system developmentEphrin type-A receptor 2Homo sapiens (human)
vasculogenesisEphrin type-A receptor 2Homo sapiens (human)
osteoblast differentiationEphrin type-A receptor 2Homo sapiens (human)
blood vessel endothelial cell proliferation involved in sprouting angiogenesisEphrin type-A receptor 2Homo sapiens (human)
inflammatory responseEphrin type-A receptor 2Homo sapiens (human)
cell adhesionEphrin type-A receptor 2Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageEphrin type-A receptor 2Homo sapiens (human)
regulation of lamellipodium assemblyEphrin type-A receptor 2Homo sapiens (human)
notochord formationEphrin type-A receptor 2Homo sapiens (human)
cell migrationEphrin type-A receptor 2Homo sapiens (human)
negative regulation of angiogenesisEphrin type-A receptor 2Homo sapiens (human)
neural tube developmentEphrin type-A receptor 2Homo sapiens (human)
neuron differentiationEphrin type-A receptor 2Homo sapiens (human)
keratinocyte differentiationEphrin type-A receptor 2Homo sapiens (human)
osteoclast differentiationEphrin type-A receptor 2Homo sapiens (human)
positive regulation of cell migrationEphrin type-A receptor 2Homo sapiens (human)
negative regulation of chemokine productionEphrin type-A receptor 2Homo sapiens (human)
mammary gland epithelial cell proliferationEphrin type-A receptor 2Homo sapiens (human)
regulation of cell adhesion mediated by integrinEphrin type-A receptor 2Homo sapiens (human)
post-anal tail morphogenesisEphrin type-A receptor 2Homo sapiens (human)
regulation of blood vessel endothelial cell migrationEphrin type-A receptor 2Homo sapiens (human)
regulation of angiogenesisEphrin type-A receptor 2Homo sapiens (human)
cAMP metabolic processEphrin type-A receptor 2Homo sapiens (human)
symbiont entry into host cellEphrin type-A receptor 2Homo sapiens (human)
bone remodelingEphrin type-A receptor 2Homo sapiens (human)
ephrin receptor signaling pathwayEphrin type-A receptor 2Homo sapiens (human)
axial mesoderm formationEphrin type-A receptor 2Homo sapiens (human)
cell motilityEphrin type-A receptor 2Homo sapiens (human)
defense response to Gram-positive bacteriumEphrin type-A receptor 2Homo sapiens (human)
notochord cell developmentEphrin type-A receptor 2Homo sapiens (human)
cell chemotaxisEphrin type-A receptor 2Homo sapiens (human)
branching involved in mammary gland duct morphogenesisEphrin type-A receptor 2Homo sapiens (human)
lens fiber cell morphogenesisEphrin type-A receptor 2Homo sapiens (human)
regulation of ERK1 and ERK2 cascadeEphrin type-A receptor 2Homo sapiens (human)
response to growth factorEphrin type-A receptor 2Homo sapiens (human)
protein localization to plasma membraneEphrin type-A receptor 2Homo sapiens (human)
activation of GTPase activityEphrin type-A receptor 2Homo sapiens (human)
negative regulation of lymphangiogenesisEphrin type-A receptor 2Homo sapiens (human)
positive regulation of protein localization to plasma membraneEphrin type-A receptor 2Homo sapiens (human)
positive regulation of bicellular tight junction assemblyEphrin type-A receptor 2Homo sapiens (human)
pericyte cell differentiationEphrin type-A receptor 2Homo sapiens (human)
positive regulation of kinase activityEphrin type-A receptor 2Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayEphrin type-A receptor 2Homo sapiens (human)
multicellular organism developmentEphrin type-A receptor 2Homo sapiens (human)
cell surface bile acid receptor signaling pathwayG-protein coupled bile acid receptor 1Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeG-protein coupled bile acid receptor 1Homo sapiens (human)
cellular response to bile acidG-protein coupled bile acid receptor 1Homo sapiens (human)
positive regulation of cholangiocyte proliferationG-protein coupled bile acid receptor 1Homo sapiens (human)
regulation of bicellular tight junction assemblyG-protein coupled bile acid receptor 1Homo sapiens (human)
G protein-coupled receptor signaling pathwayG-protein coupled bile acid receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (27)

Processvia Protein(s)Taxonomy
cysteine-type endopeptidase activityUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
cysteine-type deubiquitinase activityUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
protein bindingUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
cyclin bindingUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
ubiquitin protein ligase bindingUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
identical protein bindingUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
metal ion bindingUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
DNA-binding transcription factor activityVitamin D3 receptorHomo sapiens (human)
vitamin D response element bindingVitamin D3 receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificVitamin D3 receptorHomo sapiens (human)
DNA bindingVitamin D3 receptorHomo sapiens (human)
nuclear receptor activityVitamin D3 receptorHomo sapiens (human)
protein bindingVitamin D3 receptorHomo sapiens (human)
zinc ion bindingVitamin D3 receptorHomo sapiens (human)
bile acid nuclear receptor activityVitamin D3 receptorHomo sapiens (human)
nuclear retinoid X receptor bindingVitamin D3 receptorHomo sapiens (human)
calcitriol bindingVitamin D3 receptorHomo sapiens (human)
lithocholic acid bindingVitamin D3 receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingVitamin D3 receptorHomo sapiens (human)
virus receptor activityEphrin type-A receptor 2Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activityEphrin type-A receptor 2Homo sapiens (human)
ephrin receptor activityEphrin type-A receptor 2Homo sapiens (human)
protein bindingEphrin type-A receptor 2Homo sapiens (human)
ATP bindingEphrin type-A receptor 2Homo sapiens (human)
growth factor bindingEphrin type-A receptor 2Homo sapiens (human)
cadherin bindingEphrin type-A receptor 2Homo sapiens (human)
molecular function activator activityEphrin type-A receptor 2Homo sapiens (human)
protein bindingG-protein coupled bile acid receptor 1Homo sapiens (human)
bile acid receptor activityG-protein coupled bile acid receptor 1Homo sapiens (human)
G protein-coupled bile acid receptor activityG-protein coupled bile acid receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (18)

Processvia Protein(s)Taxonomy
nucleoplasmUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
centrosomeUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
membraneUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
perinuclear region of cytoplasmUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
cytoplasmUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
nucleusVitamin D3 receptorHomo sapiens (human)
nucleusVitamin D3 receptorHomo sapiens (human)
nucleoplasmVitamin D3 receptorHomo sapiens (human)
cytosolVitamin D3 receptorHomo sapiens (human)
RNA polymerase II transcription regulator complexVitamin D3 receptorHomo sapiens (human)
chromatinVitamin D3 receptorHomo sapiens (human)
receptor complexVitamin D3 receptorHomo sapiens (human)
plasma membraneEphrin type-A receptor 2Homo sapiens (human)
focal adhesionEphrin type-A receptor 2Homo sapiens (human)
cell surfaceEphrin type-A receptor 2Homo sapiens (human)
lamellipodiumEphrin type-A receptor 2Homo sapiens (human)
leading edge membraneEphrin type-A receptor 2Homo sapiens (human)
lamellipodium membraneEphrin type-A receptor 2Homo sapiens (human)
ruffle membraneEphrin type-A receptor 2Homo sapiens (human)
tight junctionEphrin type-A receptor 2Homo sapiens (human)
receptor complexEphrin type-A receptor 2Homo sapiens (human)
plasma membraneEphrin type-A receptor 2Homo sapiens (human)
cytoplasmG-protein coupled bile acid receptor 1Homo sapiens (human)
plasma membraneG-protein coupled bile acid receptor 1Homo sapiens (human)
receptor complexG-protein coupled bile acid receptor 1Homo sapiens (human)
plasma membraneG-protein coupled bile acid receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (19)

Assay IDTitleYearJournalArticle
AID680611TP_TRANSPORTER: inhibition of Estradiol-17beta-D-glucuronide uptake by Glycolithocholate at a concentration of 10 uM in membrane vesicle from MRP8-expressing LLC-PK1 cells2005Molecular pharmacology, Feb, Volume: 67, Issue:2
Transport of bile acids, sulfated steroids, estradiol 17-beta-D-glucuronide, and leukotriene C4 by human multidrug resistance protein 8 (ABCC11).
AID728703Reversible inhibition of ephrin-A1-Fc binding to EphA2-Fc receptor (unknown origin) after 1 hr by ELISA2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor.
AID324923Agonist activity at human TGR5 expressed in CHO cells by luciferase assay2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.
AID324924Agonist activity at human TGR5 expressed in CHO cells by luciferase assay relative to lithocholic acid2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.
AID728707Antagonist activity at EphA2 in human PC3 cells assessed as inhibition of ephrin-A1-Fc-stimulated EphA2 phosphorylation pretreated for 20 mins by sandwich ELISA2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor.
AID728719Inhibition of ephrin-A1-Fc binding to EphA2-Fc receptor (unknown origin) after 1 hr by ELISA2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor.
AID1744189Inhibition of rat alpha-2,3-O-ST3GALI assessed as reduction in sialylated-product formation at 1 mM using p-nitrophenyl T-antigen and CMP-NeuSAc incubated for 15 mins by reverse-phase HPLC analysis relative to control2021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
Sialyltransferase Inhibitors Suppress Breast Cancer Metastasis.
AID1744188Inhibition of rat alpha-2,3-O-ST3GALI assessed as reduction in sialylated-product formation at 500 uM using p-nitrophenyl T-antigen and CMP-NeuSAc incubated for 15 mins by reverse-phase HPLC analysis relative to control2021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
Sialyltransferase Inhibitors Suppress Breast Cancer Metastasis.
AID1277420Cytotoxicity against HEK293T cells assessed as reduction in cell viability after 18 hrs by CellTiter-Glo luminescence assay2016European journal of medicinal chemistry, Feb-15, Volume: 109Synthesis and evaluation of vitamin D receptor-mediated activities of cholesterol and vitamin D metabolites.
AID1277417Antagonist activity against VP16 tagged-VDR-LBD (unknown origin) expressed in HEK293T cells assessed as inhibition of 1,25-dihydroxyvitamin D3-induced SRC1 coactivator peptide recruitment after 16 hrs by luciferase reporter gene based two hybrid assay2016European journal of medicinal chemistry, Feb-15, Volume: 109Synthesis and evaluation of vitamin D receptor-mediated activities of cholesterol and vitamin D metabolites.
AID1744185Inhibition of rat alpha-2,3-N-ST3GALIII assessed as reduction in sialylated-product formation using Gal-beta1-4Glc and CMP-NeuSAc incubated for 1.5 hrs by reverse-phase HPLC analysis2021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
Sialyltransferase Inhibitors Suppress Breast Cancer Metastasis.
AID681894TP_TRANSPORTER: inhibition of Taurocholate uptake in the presence of Lithoglycocholate at a concentration of 20uM in membrane vesicles from MRP4-expressing V79 cells2003Hepatology (Baltimore, Md.), Aug, Volume: 38, Issue:2
Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane.
AID679571TP_TRANSPORTER: inhibition of Taurocholate uptake (Taurochorate: 10 uM, Glycholithocholate: 100 uM) in Xenopus laevis oocytes1994The Journal of clinical investigation, Mar, Volume: 93, Issue:3
Molecular cloning, chromosomal localization, and functional characterization of a human liver Na+/bile acid cotransporter.
AID1277413Agonist activity at VDR-LBD (unknown origin) expressed in Escherichia coli assessed as SRC2-3 coactivator peptide recruitment after 30 mins by fluorescence polarization assay2016European journal of medicinal chemistry, Feb-15, Volume: 109Synthesis and evaluation of vitamin D receptor-mediated activities of cholesterol and vitamin D metabolites.
AID1277414Antagonist activity against VDR-LBD (unknown origin) expressed in Escherichia coli assessed as inhibition of VDR agonist LG190178-induced SRC2-3 coactivator peptide recruitment after 30 mins by fluorescence polarization assay2016European journal of medicinal chemistry, Feb-15, Volume: 109Synthesis and evaluation of vitamin D receptor-mediated activities of cholesterol and vitamin D metabolites.
AID1277415Agonist activity at VP16 tagged-VDR-LBD (unknown origin) expressed in HEK293T cells assessed as SRC1 coactivator peptide recruitment after 16 hrs by luciferase reporter gene based two hybrid assay2016European journal of medicinal chemistry, Feb-15, Volume: 109Synthesis and evaluation of vitamin D receptor-mediated activities of cholesterol and vitamin D metabolites.
AID1744187Inhibition of human alpha-2,6-ST6GAL1 assessed as reduction in sialylated-product formation at 100 uM using Gal-beta1-4GlcNac and CMP-NeuSAc incubated for 15 mins by reverse-phase HPLC analysis relative to control2021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
Sialyltransferase Inhibitors Suppress Breast Cancer Metastasis.
AID1802687Di-UB K63-2 Hydrolysis Assay from Article 10.1016/j.chembiol.2017.03.002: \\Lithocholic Acid Hydroxyamide Destabilizes Cyclin D1 and Induces G0/G1 Arrest by Inhibiting Deubiquitinase USP2a.\\
AID1802686Ub-AMC-Hydrolysis Assay from Article 10.1016/j.chembiol.2017.03.002: \\Lithocholic Acid Hydroxyamide Destabilizes Cyclin D1 and Induces G0/G1 Arrest by Inhibiting Deubiquitinase USP2a.\\
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (30)

TimeframeStudies, This Drug (%)All Drugs %
pre-199012 (40.00)18.7374
1990's7 (23.33)18.2507
2000's6 (20.00)29.6817
2010's4 (13.33)24.3611
2020's1 (3.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.23

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.23 (24.57)
Research Supply Index3.50 (2.92)
Research Growth Index4.39 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.23)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other32 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]